(Q35637346)

English

Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s).

scientific article published on June 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

9 August 2017

Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s). (English)

1 reference

Europe PubMed Central

9 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

randomized experiment

1 reference

based on heuristic

inferred from title

lopinavir/ritonavir

1 reference

based on heuristic

inferred from title

Kevin Yarasheski

object named as

Kevin Yarasheski

3

0 references

object named as

Pablo Tebas

1

0 references

Cecilia M Shikuma

9

object named as

Cecilia Shikuma

1 reference

Europe PubMed Central

9 August 2017

8

object named as

Ann C Collier

1 reference

Europe PubMed Central

9 August 2017

Margaret A Fischl

5

object named as

Margaret A Fischl

1 reference

Europe PubMed Central

9 August 2017

author name string

Jiameng Zhang

2

1 reference

Europe PubMed Central

9 August 2017

Scott Evans

4

1 reference

Europe PubMed Central

9 August 2017

Abby Shevitz

6

1 reference

Europe PubMed Central

9 August 2017

Judith Feinberg

7

1 reference

Europe PubMed Central

9 August 2017

Barbara Brizz

10

1 reference

Europe PubMed Central

9 August 2017

Fred Sattler

11

1 reference

Europe PubMed Central

9 August 2017

AIDS Clinical Trials Group (ACTG)

12

1 reference

Europe PubMed Central

9 August 2017

language of work or name

0 references

publication date

1 June 2007

1 reference

Europe PubMed Central

9 August 2017

Journal of Acquired Immune Deficiency Syndromes

1 reference

Europe PubMed Central

9 August 2017

45

1 reference

Europe PubMed Central

9 August 2017

2

1 reference

Europe PubMed Central

9 August 2017

193-200

1 reference

Europe PubMed Central

9 August 2017

randomized experiment

0 references

Fat distribution in men with HIV infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4441526

27 July 2018

Cardiovascular risk and body-fat abnormalities in HIV-infected adults

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4441526

27 July 2018

Tolerability and safety of HIV protease inhibitors in adults

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4441526

27 July 2018

Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4441526

27 July 2018

What is HIV-associated lipodystrophy? Defining fat distribution changes in HIV infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4441526

27 July 2018

Incidence of adipose tissue alterations in first-line antiretroviral therapy: the LipoICoNa Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4441526

27 July 2018

Switching effective antiretroviral therapy: a review.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4441526

27 July 2018

TNF-alpha promoter region gene polymorphisms in HIV-positive patients with lipodystrophy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4441526

27 July 2018

Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4441526

27 July 2018

Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4441526

27 July 2018

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4441526

27 July 2018

Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4441526

25 September 2018

Fat distribution in HIV-infected women in the United States: DEXA substudy in the Women's Interagency HIV Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4441526

25 September 2018

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4441526

25 September 2018

Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4441526

25 September 2018

No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4441526

25 September 2018

Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4441526

25 September 2018

Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4441526

25 September 2018

A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4441526

25 September 2018

Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4441526

25 September 2018

Hepatitis C virus in patients with HIV infection and lipodystrophy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4441526

25 September 2018

Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4441526

25 September 2018

Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4441526

25 September 2018

Clinical assessment of HIV-associated lipodystrophy in an ambulatory population

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4441526

25 September 2018

Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4441526

25 September 2018

Is there a relationship between hepatitis C virus infection and antiretroviral-associated lipoatrophy?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4441526

25 September 2018

A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4441526

25 September 2018

Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4441526

25 September 2018

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4441526

25 September 2018

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4441526

25 September 2018

Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/17527093

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fat distribution in HIV-infected patients reporting truncal enlargement quantified by whole-body magnetic resonance imaging

1 reference

https://pubmed.ncbi.nlm.nih.gov/17527093

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1097/QAI.0B013E318042E204

1 reference

Europe PubMed Central

9 August 2017

release_q7wts7qhs5e5hmf3c2qct2bznq

1 reference

https://api.fatcat.wiki/v0/release/q7wts7qhs5e5hmf3c2qct2bznq

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

9 August 2017

1 reference

Europe PubMed Central

9 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35637346&oldid=1946345539"